echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The latest research results of Zhang Xiaohui's team from the People's Hospital Institute of Hematology are published in "Blood"

    The latest research results of Zhang Xiaohui's team from the People's Hospital Institute of Hematology are published in "Blood"

    • Last Update: 2022-04-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On January 20, 2022, the team of Professor Zhang Xiaohui, Institute of Hematology, Peking University People's Hospital, on low-dose rituximab (LD-RTX) combined with all-trans retinoic acid (ATRA) in the treatment of hormone-resistant or recurrent immune thrombocytopenia Symptomatic (ITP) research results, published in the international high-level journal Blood , and selected to provide Continuing medical education (CME)


    All-Trans Retinoic Acid Plus Low-Dose Rituximab Vs Low-Dose Rituximab in Corticosteroid-Resistant or Relapsed ITP The study is a multi-center, open-label, randomized controlled, investigator-initiated clinical trial comparing ATRA combined with LD-RTX and LD-RTX monotherapy for hormone-resistant/relapsed ITP.


    The results of the study showed that the 1-year overall response rate in the ATRA combined with LD-RTX group was significantly higher than that in the LD-RTX single-agent group (80% vs 59%, rate difference 0.


    The first author of the research results is Wu Yejun, a 2016 eight-year clinical student , and the corresponding authors are Huang Xiaojun, director of the Institute of Hematology, Peking University People's Hospital, and Zhang Xiaohui, deputy director


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.